Clinical trials: Sublesional Bone Loss Secondary to SCI
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date.
- Trial name
- Chronic Romo (NCT04232657)
- Testing
- Romosozumab, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development